



\$1653
RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

PATENT APPLICATION

File No: 97-44D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : David A. Adler, James L. Holloway, Nand Baindur, Stephanie Beigel-
Orme, Paul O. Sheppard
Serial No. : 10/091,166
Group Art Unit : 1653
Examiner :
Filed : March 5, 2002
For : NOVEL BETA-DEFENSINS

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement (in duplicate)
2. PTO-1449 Form
3. 48 References
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on September 16, 2002.



Lara Russell

Information Disclosure Statement

Page 2 of 2

Applicant(s): Adler et al.

Serial No.: 10/091,166

Filed: March 5, 2002

For: NOVEL BETA-DEFENSINS

Since this Information Disclosure Statement is submitted after receipt of an Office Action in the above-identified patent application, please charge a fee of \$180 to Deposit Account No. 26-0290 under 37 C.F.R. §§1.97(d) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,



Brian J. Walsh

Registration No. 45,543

Direct Dial - (206) 442-6540



PATENT APPLICATION

File No: 97-44D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : David A. Adler, James L. Holloway, Nand Baindur, Stephanie
Beigel-Orme, Paul O. Sheppard
Serial No. : 10/091,166,
Group Art Unit : 1653
Examiner :
Filed : March 5, 2002
For : NOVEL BETA-DEFENSINS
Date Submitted : September 16, 2002

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with C.F.R. §§1.97 *et. seq.*, references listed on the enclosed 1449 form(s) are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

The present application is a divisional of U.S. Patent Application Serial No. 09/636,399, filed August 10, 2000, which is a continuation-in-part of U.S. Patent Application Serial No. 09/344,097, filed June 25, 1999, which is a continuation-in-part of U.S. Patent Application Serial No. 09/150,786, filed September 10, 1998, which claims the benefit of U.S. Patent Application Serial No. 60/064,294, filed November 5, 1997, and U.S. Patent Application Serial No. 60/058,335, filed September 10, 1997.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

09/23/2002 SSSESHE1 00000088 260290 10091166

01 FC:126 180.00 CH

SEP 24 2002

TECH CENTER 1609/2990 1 of 6

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):
David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. Sheppard

Filing Date:
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	95/32287	11/30/95	PCT		
	A2	99/06554	02/11/99	PCT		
	A3	00/07612	02/17/00	PCT		
	A4	00/46245	08/10/00	PCT		
	A5	01/42467	06/14/00	PCT		
	A6	02/04487	01/17/02	PCT		
	A7	02/40512	05/23/02	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A8	Jia et al., "Discovery of new human beta-defensins using a genomics-based approach," <u>Gene</u> , 263(1-2):211-218 (Jan. 2001).
	A9	Lehrer et al. "Defensins: antimicrobial and cytotoxic peptides of mammalian cells," <u>Annu Rev Immunol</u> , 11:105-128 (1993). Review.
	A10	Harder et al. "A peptide antibiotic from human skin," <u>Nature</u> , 387(6636):861 (June 26, 1997).
	A11	Incyte Pharmaceuticals, Inc. clone, 1996:INC1433022.
	A12	Incyte Pharmaceuticals, Inc. LIBRARY, 1996:BEPINON01.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 2 of 6

FORM 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):
David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. Sheppard

Filing Date:
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED
SEP 24 2002

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A13	Incyte Pharmaceuticals, Inc. LIBRARY, 1996: LPARNOT02.
	A14	Selsted et al., "Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils," <u>J Biol Chem.</u> , 268(9):6641-6648 (March 25, 1993).
	A15	Bensch et al., "hBD-1: a novel beta-defensin from human plasma," <u>FEBS Lett.</u> , 368(2):331-335 (July 17, 1995).
	A16	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <u>Science</u> , 247(4948):1306-1310 (March 16, 1990).
	A17	Wells, J.A., "Additivity of mutational effects in proteins," <u>Biochemistry</u> , 29(37):8509-8517 (Sept. 18, 1990).
	A18	Liu et al., "Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation," <u>Gene</u> , 222(2):237-244 (Nov. 19, 1998).
	A19	Porter et al., "Broad-spectrum antimicrobial activity of human intestinal defensin 5," <u>Infect Immun.</u> , 65(6):2396-2401 (June 1997).
	A20	Daher et al., "Direct inactivation of viruses by human granulocyte defensins," <u>J Virol.</u> , 60(3):1068-1074 (Dec. 1986).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 3 of 6

FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):

David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. Sheppard

Filing Date:

March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A21		Martin et al., "Defensins and other endogenous peptide antibiotics of vertebrates," <u>J Leukoc Biol.</u> , <u>58</u> (2):128-136 (Aug. 1995). Review.
	A22		Ouellette et al., "Paneth cell defensins: endogenous peptide components of intestinal host defense," <u>FASEB J.</u> , <u>10</u> (11):1280-1289 (Sept. 1996). Review.
	A23		Lichtenstein et al., "In vitro tumor cell cytotoxicity mediated by peptide defensins of human and rabbit granulocytes," <u>Blood</u> , <u>68</u> (6):1407-1410 (Dec. 1986).
	A24		Zhu et al., "Isolation and structure of corticostatin peptides from rabbit fetal and adult lung," <u>Proc Natl Acad Sci U S A.</u> , <u>85</u> (2):592-596 (Jan. 1988).
	A25		Territo et al., "Monocyte-chemotactic activity of defensins from human neutrophils," <u>J Clin Invest.</u> , <u>84</u> (6):2017-2020 (Dec. 1989).
	A26		Tamura et al., "A marked decrease in defensin mRNA in the only case of congenital neutrophil-specific granule deficiency reported in Japan," <u>Int J Hematol.</u> , <u>59</u> (2):137-142 (Feb. 1994).
	A27		Higazi et al., "Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells," <u>J Biol Chem.</u> , <u>271</u> (30):17650-5 (July 26, 1996).
	A28		Yang et al., "Mammalian defensins in immunity: more than just microbicidal," <u>Trends Immunol.</u> , <u>23</u> (6):291-6 (June 2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900
SEP 24 2002

SEP 20 2002

SEP 24 2002

TECH CENTER 1600/2900
Sheet 1 of 6FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):
David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. SheppardFiling Date:
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A29		Circo et al., "Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFBI polymorphism," <u>Biochem Biophys Res Commun.</u> , 293(1):586-92 (April 26, 2002).
	A30		Schibli et al., "The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus," <u>J Biol Chem.</u> , 277(10):8279-89 (March 8, 2002).
	A31		Harder et al., "Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic," <u>J Biol Chem.</u> , 276(8):5707-13 (Feb. 23, 2001).
	A32		Goldman et al., "Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis," <u>Cell</u> , 88(4):553-60 (Feb. 21, 1997).
	A33		Smith et al., "Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid," <u>Cell</u> , 85(2):229-36 (April 19, 1996).
	A34		Davies et al., "CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium," <u>Am J Respir Cell Mol Biol.</u> , 16(6):657-63 (June 1997).
	A35		Dunsche et al., "The novel human beta-defensin-3 is widely expressed in oral tissues," <u>Eur. J. Oral. Sci.</u> , 109:121-124 (2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 24 2002

TECH CENTER 1600/2900
Sheet 1 of 6FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

Applicant(s):

David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. SheppardFiling Date:
March 5, 2002

Group: 1653

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A36		Cullor et al., "In vitro antimicrobial activity of defensins against ocular pathogens," <u>Arch Ophthalmol.</u> , 108(6):861-864 (June 1990).
	A37		Schwab et al., "Corneal storage medium preservation with defensins," <u>Cornea</u> , 11(5):370-375 (Sept. 1992).
	A38		Yeh et al., "Single-dose pharmacokinetics of indinavir and the effect of food," <u>Antimicrob Agents Chemother.</u> , 42(2):332-338 (Feb. 1998).
	A39		Haynes et al., "Innate defence of the eye by antimicrobial defensin peptides," <u>Lancet</u> , 352(9126):451-452 (Aug. 8, 1998).
	A40		Haynes et al., "Antimicrobial defensin peptides of the human ocular surface," <u>Br J Ophthalmol.</u> , 83(6):737-41 (June 1999).
	A41		Sawicki et al., "Contraceptive potential of peptide antibiotics," <u>Lancet</u> , 353(9151):464-5 (Feb. 6, 1999).
	A42		Garcia et al., "Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of <i>Xenopus</i> oocytes and the induction of macrophage chemoattraction," <u>Cell Tissue Res.</u> , 306(2):257-64 (Nov. 2001).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 24 2002

TECH CENTER 1609/2930 6 of 6

FORM 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):

David A. Adler, James L. Holloway,
Nand Baindur, Stephanie Beigel-Orme,
Paul O. Sheppard

Filing Date:

March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A43	Zasloff, M., "Antimicrobial peptides of multicellular organisms," <u>Nature</u> , 415:389-395 (Jan. 2002).
	A44	Krisanaprakornkit et al., "Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family," <u>J Immunol.</u> , 168(1):316-324 (Jan. 1, 2002).
	A45	Garcia et al., "Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity," <u>FASEB J.</u> , express article 10.1096/fj.00-0865fje, published online on June 18, 2001.
	A46	Duits et al., "Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids," <u>Biochem Biophys Res Commun.</u> , 280(2):522-525 (Jan. 2001).
	A47	Hancock et al., "Antibiotic resistance in <i>Pseudomonas aeruginosa</i> : mechanisms and impact on treatment," <u>Drug Resist Updat.</u> , 3(4):247-255 (Aug. 2000).
	A48	Biragyn et al., "DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses," <u>Blood</u> , 100(4):1153-1159 (Aug. 15, 2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.